Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care Français
TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada.
Country Lead, Canada and General Manager, Specialty Care
"This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healthcare around the globe. The company is building on this momentum, leveraging next-gen technology and AI, to turn breakthrough science into reality for patients. I feel privileged to be back home in Canada working with our talented teams; I'm confident that their patient-focused approach will deliver new solutions that will continue to benefit Canadian patients."
Guy brings over two decades of pharmaceutical industry experience, including 13 years with Sanofi in global, US, and Canadian leadership roles, most recently as the Immunology Franchise Head in Canada. His prior positions within Sanofi include International Strategic Marketing Director based in the Czech Republic, Respiratory Global Brand Lead based in the US, and Regional Business Director in the US affiliate.
A Canadian citizen, Guy holds a B.Sc. in Applied Chemistry & Biology from Toronto Metropolitan University, an M.Sc. in Biomedical Sciences from the University of Bradford (UK), and an MBA from Rutgers University (USA).
With over 2,000 employees across the country, Sanofi's operations in Canada include R&D, Commercial, the country's largest biomanufacturing facility, and an AI Centre of Excellence. The company is uniquely positioned to deliver across the full life sciences value chain within Canada.
As Country Lead, Guy will chair the Canada Country Council, which includes:
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
In Canada, we employ over 2,000 people and invest 20% of our revenue annually in biopharma research, representing $1.2 billion CAD in R&D over the last decade, creating jobs, business, and opportunity throughout the country. We are the largest biomanufacturing facility in Canada and are on track to deliver over $2 billion in new infrastructure investments by 2028, including two new vaccine manufacturing facilities at our Toronto Campus. For more than 110 years, we have been working in collaborative partnerships with a vast network of healthcare stakeholders and are committed to creating a healthier future in Canada.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
17 minutes ago
- Cision Canada
TALON METALS ANNOUNCES UPSIZED $39 MILLION FINANCING COMPRISED OF $25 MILLION BROKERED PRIVATE PLACEMENT AND CONCURRENT $14 MILLION NON-BROKERED PRIVATE PLACEMENT
ROAD TOWN, Tortola, , June 9, 2025 /CNW/ - Talon Metals Corp. (TSX: TLO) (OTC Pink: TLOFF) (" Talon" or the " Company") is pleased to announce that as a result of strong investor demand, the Company has amended its agreement with Canaccord Genuity Corp. (" Canaccord Genuity") on behalf of a syndicate of underwriters (the " Underwriters") to increase the size of its previously announced "bought deal" private placement of units of the Company (the " LIFE Units") to raise gross proceeds of $25,300,000 (the " LIFE Offering"), consisting of 115,000,000 LIFE Units at a price of $0.22 per LIFE Unit (the " Offering Price"). Concurrent with the LIFE Offering, the Company plans to complete a non-brokered private placement of up to 62,227,274 units of the Company (the " Non-LIFE Units" and, together with the LIFE Units, the " Units") at the Offering Price per Non-LIFE Unit for aggregate gross proceeds of up to approximately $13,690,000 (the " Non-LIFE Offering" and, together with the LIFE Offering, the " Offerings"). The Non-LIFE Units will be issued on the same terms as the LIFE Units. The Non-LIFE Units may be offered to purchasers resident in Canada pursuant to applicable prospectus exemptions, other than the Listed Issuer Financing Exemption (as defined below), in accordance with applicable laws, and may also be offered in other qualifying jurisdictions outside of Canada on a private placement basis pursuant to relevant prospectus or registration exemptions in accordance with applicable laws. Any securities issued under the Non-LIFE Offering to purchasers resident in Canada will be subject to a hold period in accordance with applicable Canadian securities laws, expiring four months and one day following the issue date of the Non-LIFE Units. The Non-LIFE Offering will be completed with certain directors, officers and affiliates of Pallinghurst Nickel International Ltd. Each Unit will be comprised of one common share of the Company (a " Common Share") and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a " Warrant"). Each Warrant will entitle the holder thereof to acquire one Common Share (a " Warrant Share") at a price of $0.28 per Warrant Share for a period of 36 months from the closing of the LIFE Offering or Non-LIFE Offering, as applicable. In the event that the closing price of the Common Shares on the Toronto Stock Exchange (the " TSX") (or such other Canadian stock exchange on which the Common Shares are then listed) for twenty (20) consecutive trading days exceeds $0.56, the Company may, within 10 business days of the occurrence of such event, deliver a notice (including by way of a news release) to the holders of Warrants accelerating the expiry date of the Warrants to the date that is 30 days following the date of such notice. The LIFE Units will be offered pursuant to Part 5A of National Instrument 45-106 – Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the " Listed Issuer Financing Exemption"), to purchasers resident in Canada (other than the province of Québec), and in other qualifying jurisdictions outside of Canada that are mutually agreed to by the Company and the Underwriters on a private placement basis pursuant to relevant prospectus or registration exemptions in accordance with applicable laws. The securities issued under the LIFE Offering to Canadian subscribers will not be subject to a hold period in Canada. There is an amended and restated offering document related to the LIFE Offering (the " Offering Document") that can be accessed under the Company's profile on SEDAR+ at and on the Company's website at Prospective investors should read the Offering Document before making an investment decision. The Company intends to use the net proceeds from the Offerings to advance the Tamarack Nickel Project and for general and administrative expenses and working capital purposes, as further described in the Offering Document. The Offerings are expected to close on or about June 19, 2025, or such other date as the Company and Canaccord Genuity may agree (the " Closing Date"). The Non-LIFE Offering may close on a date subsequent to or prior to the closing date of the LIFE Offering at the discretion of the Company. The Offerings are subject to the Company receiving all necessary regulatory approvals, including the approvals of the TSX. The closing of the LIFE Offering is not conditional upon closing of the Non-LIFE Offering, and the closing of the Non-LIFE Offering is not conditional upon closing of the LIFE Offering. The Units (and the underlying securities) to be offered pursuant to the Offerings have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the " U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About Talon Talon is a TSX-listed base metals company in a joint venture with Rio Tinto on the high-grade Tamarack Nickel-Copper-Cobalt Project located in central Minnesota. Talon's shares are also traded in the US over the OTC market under the symbol TLOFF. The Tamarack Nickel Project comprises a large land position (18km of strike length) with additional high-grade intercepts outside the current resource area. Talon has an earn-in right to acquire up to 60% of the Tamarack Nickel Project and currently owns 51%. Talon is focused on (i) expanding and infilling its current high-grade nickel mineralization resource prepared in accordance with NI 43-101 to shape a mine plan for submission to Minnesota regulators, and (ii) following up on additional high-grade nickel mineralization in the Tamarack Intrusive Complex. Talon has a neutrality and workforce development agreement in place with the United Steelworkers union. Talon's Beulah Mineral Processing Facility in Mercer County was selected by the US Department of Energy for US$114.8 million funding grant from the Bipartisan Infrastructure Law and the US Department of Defense awarded Talon a grant of US$20.6 million to support and accelerate Talon's exploration efforts in both Minnesota and Michigan. Talon has well-qualified experienced exploration, mine development, external affairs and mine permitting teams. Forward-Looking Statements This news release contains certain "forward-looking statements". All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements reflect the current expectations and beliefs of the Company based on information currently available to the Company. Such forward-looking statements include statements relating to the Offerings, including the completion and anticipated timing for completion of the Offerings, the potential size of the Offerings, the Company's intended use of the net proceeds of the Offerings, the receipt of all necessary regulatory approvals, including the approvals of the TSX, and the Company's exploration and development plans. Forward-looking statements are subject to significant risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.
Vancouver Sun
23 minutes ago
- Vancouver Sun
Elbows-up tourism surge could see sector ‘eke out' a gain even as Americans stay away
From the front desk of Hotel Bedford in Goderich, Ont., Lynda Cross welcomes guests from regions ranging from southern Ontario to the South Pacific. 'A lot of them come from Toronto,' said the manager, standing just inside the Romanesque arches of the 129-year-old establishment. 'Just lately, we've had a few groups come from Australia' — a first, she said. But one crop of tourists has been conspicuously absent this year: Americans. 'May and June have been slow.' Plan your next getaway with Travel Time, featuring travel deals, destinations and gear. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Travel Time will soon be in your inbox. Please try again Interested in more newsletters? Browse here. A groundswell of economic patriotism has stoked curiosity in Canadian destinations, fuelling a domestic bookings surge as travellers turn away from cross-border trips. But a drop in American visitors north of the border and fears that many Canadians will simply stay home to save money has many wondering whether homegrown and overseas tourism can make up for the stateside decline. Canadian vacationers' boycotting the U.S. could net this country's tourism sector up to $8.8 billion in extra business this year as travellers explore spots closer to home, according to a report from the Conference Board of Canada. An April survey on travel intentions prompted the group to predict a windfall despite fewer border crossings this year by American tourists — Canada's largest source of inbound travellers by far. The number of Americans who visited Canada by car fell nearly 11 per cent in April compared with the same month last year, the third straight month of year-over-year decreases, according to Statistics Canada. While trip numbers for Canadians heading to the U.S. have fallen off far more steeply as part of a backlash against U.S. President Donald Trump's tariffs and '51st state' threats, Americans' more moderate pullback owes to factors ranging from pinched pocketbooks to fears of feeling unwelcome to angst over the border crossing on the drive home. The American retreat could hit communities that hug the border especially hard. 'Border towns that have tended to experience the shorter, more frequent back-and-forth visits — those are going to be communities that are going to be more heavily affected,' said Andrew Siegwart, who heads the Tourism Industry Association of Ontario. Duty-free stores have seen their revenue drop by 60 to 80 per cent in the last few months, according to an association representing 32 of the mostly mom-and-pop shops. Whether overseas travellers can make up for much of the lower American traffic across the country is questionable. Visitor volume from China, previously a key source of tourists, sat at 40 per cent of 2019 levels last year amid ongoing restrictions on group travel to Canada, according to Destination Canada. The federal government imposed new visa requirements on Mexican visitors last year, making it harder for tourists from that country to come. 'Travel from India has also been down for a number of reasons. So it's going to take some time,' said Siegwart. However, many America-averse Canadians are spending their travel budget in their own backyards. More than half of respondents to a survey released Monday by Ontario's travel regulator said they were more likely to make excursions closer to home, with the trend holding across all age groups. 'It could be a year where we manage to stay on par with last year, or maybe even eke out a little bit of a gain,' said Siegwart. But he acknowledged the hurdle of consumer anxiety over the economy. 'I'm cautiously optimistic,' he said, 'but it's too early to tell.' Summer bookings were either the same or higher than last year at two out of three businesses surveyed by the association in a poll released last month. John Steele, who owns seven hotels in Newfoundland and Labrador and one in Fredericton, said visitor levels look 'pretty good' at most of his properties but softer in Gander. New direct flights to St. John's from London and Paris have made it easier for international travellers to come from away. 'Air access seems to be improving for us. That's a big thing for us,' Steele said. At Okanagan Wine Country Tours in British Columbia, bookings from Europe and the United Kingdom have risen about 20 per cent year-over-year, said partner and manager Marsha Morrish. 'The traffic from Quebec is up substantially,' she added. Americans are more tepid — even those who do head north. 'They did email me to do a bit of a temperature check on how Canadians were feeling about Americans visiting,' Morrish said, referring to a Colorado couple coming up to sample Pinot Gris. While there's a chance American tourist numbers could surge, it's unlikely to happen this year, Siegwart suggested — including for corporate gatherings. 'Some convention centres, both in Ontario and across the country, have seen some drops in American conference bookings.' Much of it has to do with personal safety and security, as some workers worry about how they'll be treated at the border. 'Depending on your immigration status, depending on if you're a member of an LGBTQIA community, if your gender markers or identities on your passports are different than your gender expression — all sorts of things like that are really coming into play,' Siegwart said. 'My colleagues south of the border are a little more cautious in how they plan things because of the unpredictable way in which their administration is conducting business.' On the flip side, there's more interest from corporate event planners in Europe 'who still want to come to North America but see Canada as a safer bet.' Some Americans remain undeterred though. 'I've seen way more people from the States this year,' said Wendy Mooney, owner of Country Hideaway RV Campground, which sits barely a kilometre from the border in the B.C.'s West Kootenay region. 'Some people just fly by the seat of their pants.'
Globe and Mail
28 minutes ago
- Globe and Mail
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in 2024. The recent spree of acquisitions signifies a focus on portfolio expansion and constant pipeline innovation, given the changing landscape and spotlight on AI-driven drug discovery. Simultaneously, bigwigs in the space also enter into licensing deals and collaborations for a promising drug/candidate to strengthen and expand their portfolios in their respective core areas. Quick Take on Recent Acquisitions & Deals Pharma giant Sanofi SNY recently announced that it will acquire Blueprint Medicines for a total deal value of up to $9.5 billion to expand its portfolio in rare immunological disease and add an early-stage pipeline in immunology. The impending acquisition will add Blueprint Medicines' only marketed product, Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, to Sanofi's commercial portfolio. Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BioNTech will also receive $2 billion in non-contingent anniversary payments through 2028. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment, attracting other pharma giants as well. In May 2025, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are also being eyed. Last week, Regeneron REGN entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. M&A in Focus in 2025 Consolidation has long been a central focus in the pharma/biotech industry. This is because leading companies constantly look to diversify their revenue base in the face of dwindling sales of their high-profile drugs. Acquisitions also make sense as developing a drug/technology from scratch is costly and risky. In April, pharma giant Johnson & Johnson acquired Intra-Cellular Therapies for approximately $14.6 billion and added antidepressant drug, Caplyta, to its neuroscience portfolio. Swiss pharma bigwig Novartis NVS, too, has been on an acquisition spree. Novartis is all set to acquire San Diego-based clinical-stage biopharmaceutical company Regulus Therapeutics to strengthen its renal disease portfolio. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. In April, Germany-based Merck KGaA announced that it will acquire SpringWorks Therapeutics, Inc. for $3.9 billion to expand business in the United States. SpringWorks Therapeutics, a U.S.-based biopharma company, has a portfolio that comprises a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas. Potential Deals We expect M&A activity to accelerate further in 2025, given the massive cash reserve owned by major pharma and biotech companies. These companies will also look to utilize innovative technology to develop breakthrough treatments rapidly as the landscape evolves. Moreover, smaller biotechs often lack the necessary funds to successfully develop a drug and commercialize thereafter. The recent spotlight on the usage of AI technology for drug discovery should lure investment in this industry. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report
